Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Lieberman

Pulmonary Disease Margate, FL Medical Doctor

NPI 1134412760 CMS profile 1050488

2825 N State Road 7 Ste 305, Margate, FL 33063

Open in the dashboard

General payments

$3,882

147 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$23,608 paid to institutions, not to them · program years 2021–2022

Through program year 2025, Scott Lieberman of Margate, FL is reported in the CMS Open Payments database as having received $3,882 across 147 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $23,608 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 62nd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,083 78
2024 General $693 27
2023 General $825 29
2022 General $239 10
2021 General $12 1
2019 General $31 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Lieberman
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Scott Lieberman were reported at $2,083. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Scott Lieberman Pulmonary Disease median Middle half National median
2019 $31 $377 $109–$1,340 $163
2020 $0 $230 $56–$907 $114
2021 $12 $269 $68–$1,072 $132
2022 $239 $390 $100–$1,457 $149
2023 $825 $419 $114–$1,659 $160
2024 $693 $476 $123–$1,818 $164
2025 $2,083 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $972 43 payments
  2. Mallinckrodt Hospital Products Inc. $476 12 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $300 11 payments
  4. AstraZeneca Pharmaceuticals LP $295 10 payments
  5. Insmed, Inc. $280 15 payments
  6. Regeneron Healthcare Solutions, Inc. $266 4 payments
  7. Verona Pharma, Inc. $245 13 payments
  8. Viatris Specialty LLC $200 10 payments
  9. Actelion Pharmaceuticals US, Inc. $159 2 payments
  10. Merck Sharp & Dohme Corporation $130 6 payments
  11. Other $559 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,547 142 payments
  2. Education $335 5 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $838 36 payments
  2. ACTHAR $476 12 payments
  3. GLASSIA $300 11 payments
  4. Arikayce $280 15 payments
  5. DUPIXENT $266 4 payments
  6. Ohtuvayre $245 13 payments
  7. YUPELRI $200 10 payments
  8. AIRSUPRA $187 4 payments
  9. UPTRAVI $159 2 payments
  10. OPSUMIT $159 2 payments
  11. Other $1,356 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

907

Median for Pulmonary Disease: 936

Drug cost

$268,450

Median for Pulmonary Disease: $487,987

Branded share of claims

88.3%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 172 $121,052
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 63 $48,180
Symbicort Budesonide/Formoterol Fumarate Brand 75 $20,740
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 39 $19,390
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 35 $17,392
Spiriva Respimat Tiotropium Bromide Brand 23 $13,909
Breo Ellipta Fluticasone/Vilanterol Brand 24 $9,122
Albuterol Sulfate Hfa Albuterol Sulfate Brand 270 $7,147
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 23 $2,663
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 16 $2,640

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$270,080

Medicare's payments for the services billed

Medicare patients

698

Average age 78

Services billed

3,418

378 women, 320 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 63%
Ischemic heart disease 62%
Heart failure 58%
Arthritis 57%
Chronic kidney disease 56%
Depression 50%
Diabetes 49%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $175
$175 172 —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $164
$164 — —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $70
$70 — —
Rezzayo
  • Melinta Therapeutics, Inc. $61
$61 — —
ZERBAXA
  • Merck Sharp & Dohme Corporation $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record